Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity and mortality rates. Until recently, the treatment of locally advanced or metastatic urothelial BC was based on the use of chemotherapy alone. Since 2016, five immune checkpoint inhibitors (ICIs) have b...
Main Authors: | Giandomenico Roviello, Martina Catalano, Raffaella Santi, Valeria Emma Palmieri, Gianmarco Vannini, Ilaria Camilla Galli, Eleonora Buttitta, Donata Villari, Virginia Rossi, Gabriella Nesi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4411 |
Similar Items
-
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
by: Giandomenico Roviello, et al.
Published: (2020-10-01) -
Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency
by: Nuran Sungu, et al.
Published: (2023-10-01) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2022-06-01) -
Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression
by: Youssra Salhi, et al.
Published: (2023-07-01) -
Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
by: William L. Redmond, et al.
Published: (2023-02-01)